---
title: "Moody’s Ratings Upgrades Teva to Investment Grade, Reflecting the Ongoing Execution of Pivot to Growth Strategy"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295535901.md"
description: "Moody's Ratings has upgraded Teva to investment-grade status, reflecting the successful execution of its pivot to a growth strategy. This upgrade signals improved financial stability, creditworthiness, and overall health, demonstrating Teva's ability to adapt to market conditions and capitalize on growth opportunities."
datetime: "2026-08-11T12:03:26.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295535901.md)
  - [en](https://longbridge.com/en/news/295535901.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295535901.md)
generator: "portal-rs"
---

# Moody’s Ratings Upgrades Teva to Investment Grade, Reflecting the Ongoing Execution of Pivot to Growth Strategy

Teva has recently received an upgrade from Moody's Ratings to an investment-grade status, signaling a positive shift in its performance. This upgrade showcases the company's successful implementation of its growth strategy, demonstrating its commitment to achieving long-term success. The improved rating reflects Teva's efforts to adapt to changing market conditions and capitalize on opportunities for growth, ultimately enhancing its financial stability and outlook. This development highlights the significant progress made by Teva, with the upgrade indicating a notable improvement in its creditworthiness and overall financial health.

### Related Stocks

- [TEVA.US](https://longbridge.com/en/quote/TEVA.US.md)
- [MCO.US](https://longbridge.com/en/quote/MCO.US.md)

## Related News & Research

- [Ecopipam Priority Review Could Be A Game Changer For Teva Pharmaceutical Industries (TEVA)](https://longbridge.com/en/news/296688992.md)
- [FDA accepts Teva ecopipam NDA for pediatric Tourette syndrome, grants priority review](https://longbridge.com/en/news/296355997.md)
- [Teva EVP Business Development Evan Lippman sells 18,600 shares for $680,291.28](https://longbridge.com/en/news/296394259.md)
- [Is Teva Pharmaceutical Industries (TEVA) A Bargain On Its TEV 408 Phase 2b Move?](https://longbridge.com/en/news/296006711.md)
- [Aurinia settles Teva patent suit, sets generic voclosporin launch no earlier than Dec. 7, 2036](https://longbridge.com/en/news/296394736.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**